

FORM PTO-1449 Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2		Serial No. 10/015,534	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant Burton G. Christensen et al.		Filing Date December 13, 2001	
				Group Art Unit 1627			

MAY 22 2002
 10:55 33
 PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	*4,587,046		Goodman et al.			
	previously A2	*5,463,564		Agrafiotis et al.			
	considered A3	*5,607,921		Bernard et al.			
	A4	5,891,643		Fesik et al.			
	A5	*5,962,701		Rosenau et al.			

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	*97/00244		WIPO				
	B2	*98/02186		WIPO				
	previously B3	98/16536		WIPO				
	considered B4	98/16638		WIPO				
	B5	*0306904		EPO				
	B6	*0433043		EPO				
→ me	B7	0825191		EPO				
previously considered	B8	2317173		GB				
→ me	B9	62-164609		JP				considered only to extent of translated abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
C1	*Adham et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 348:556-575 (1993)
C2	*Adham et al., Neuropharmacol. 36(4/5):569-576 (1997)
previously C3	*Alabaster, Life Sci. 60(13/14):1053-1060 (1997)
C4	*Bartow et al., Drugs 55(2):303-322 (1998)
considered C5	*Beer et al., Br. J. Pharmacol. 110:1196-1200 (1993)
C6	*Bergendal et al., Br. J. Pharmacol. 117:1009-1015 (1996)
C7	*Bergsma et al., Biochem. Biophys. Res. Comm. 183:989-995 (1992)
C8	*Boulet, Drugs 47(2):207-222 (1994)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 6/3/2005
-----------------------------	---------------------------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.

FORM PTO 1449 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION MAY 22 2002 PATENT & TRADEMARK OFFICE		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2	Serial No. 10/015,534
(Use several sheets if necessary)				Applicant Burton G. Christensen et al.	
				Filing Date December 13, 2001	Group Art Unit 1627
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
C9	*Buckley et al., Mol. Pharmacol. 35:469-476 (1989)				
C10	*Burnier et al., Exp. Opin. Invest. Drug 6(5):489-500 (1997)				
C11	*Carini et al., J. Med. Chem. 34(8):2525-2547 (1991)				
C12	*Carini et al., J. Med. Chem. 33(5):1330-1336 (1990)				
C13	*Casas et al., J. Drugs Future 22(5):481-491 (1997)				
C14	*Chiu et al., JPET 252(2):711-718 (1990)				
C15	*Cvejic et al., J. Biol. Chem. 272(43):26959-26964 (1997)				
C16	*Dixon et al., Nature 321:75-79 (1986)				
previously C17	*Duncia et al., J. Med Chem. 33(5):1312-1329 (1990)				
C18	*Dzielak, Exp. Opin. Invest. Drugs 7(5):741-751 (1998)				
considered C19	*Eglen et al., DNP 10(8):462-469 (1997)				
C20	*Eglen et al., Pharmacol. Toxicol. 78:59-68 (1996)				
C21	*Ferro et al., Br. J. Clinical. Pharmacol. 40:245-251 (1995)				
C22	*Fiorelli et al., J. Steroid. Biochem. Mol. Biol. 59(2):233-240 (1996)				
C23	*Gardiner, Exp. Opin. Invest. Drug 7(3):405-411 (1998)				
C24	*Garssen et al., Br. J. Pharmacol. 109:53-60 (1993)				
C25	*George, J. Neurochem. 69(3):1278-1285 (1997)				
C26	*Goadsby et al., Headaches 34:394-399 (1994)				
C27	*Goadsby, "Animal models of migraine: which model, why and for what"? <i>Migraine and Headache Pathophysiology</i> , Chap. 14, Ed. L. Edvinsson, Martin Dunitz Ltd., London 1999				
C28	*Green et al., J. Biol. Chem. 271(38):24029-24035 (1996)				
C29	*Green et al., Mol. Pharmacol. 41:889-893 (1992)				
C30	*Green et al., J. Biol. Chem. 269(42):26215-26219 (1994)				
C31	*Hamel et al., Mol. Pharmacol. 44:242-246 (1993)				
C32	*Heavner, DDT 1(7):295-304 (1996)				
C33	*Hebert et al., J. Biol. Chem. 271(27):16384-16392 (1996)				
C34	*Hebert et al., Biochem. Cell Biol. 76(1):1-11 (1998)				
C35	*Holzgrabe et al., DDT 3(5):214-222 (1998)				
C36	*Janssen, Drug Invest. 3(Suppl 1):1-2 (1991)				
C37	*Kahne, Curr. Opin. Chem. Biol. 1(1):130-135 (1997)				
EXAMINER 			DATE CONSIDERED 5/13/05		
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2	Serial No. 10/105534
				Applicant Burton G. Christensen et al.	
				Filing Date December 13, 2001	Group Art Unit 1627
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
	C38	*Kobilka et al., Nature 329:75-79 (1987)			
	C39	*Kretzschmar et al., Tet. Lett. 51(47):13015-13030 (1995)			
	C40	*Kukkonen et al., J. Pharmacol. Exp. Ther. 279(2):593-601 (1996)			
	C41	*Kukkonen et al., Biochem. Biophys. Res. Comm. 243(1):41-46 (1998)			
	C42	*Leboulluec et al., Bioorg. Med. Chem. Lett. 5(2):123-126 (1995)			
	C43	*Lee et al., Mol. Pharmacol. 50:140-148 (1996)			
	C44	*Liang et al., Science 274:1520-1522 (1996)			
	C45	*Liggett et al., Mol. Pharmacol. 36:641-646 (1989)			
	C46	*Lofdahl et al., Asthma 2:1523-1533 (1997)			
	C47	*Longmore et al., Br. J. Clin. Pharmacol. 42:431-441 (1996)			
	C48	*McClellan et al., Drugs 55(5):713-718 (1998)			
<i>Previously</i>	C49	*McCrea et al., Br. J. Pharmacol. 110:619-626 (1993)			
	C50	*MacLagan et al., TIPS (Suppl):88-92 (1989)			
<i>Considered</i>	C51	*Maggio et al., PNAS 90:3103-3107(1993)			
	C52	*Martel et al., Drugs Future 22(2):135-137 (1997)			
	C53	*Martin et al., Br. J. Pharmacol. 121:157-164 (1997)			
	C54	*Merlos et al., Drugs Future 22(8):850-855 (1997)			
	C55	*Monnot et al., J. Biol. Chem. 271(3):1507-1513 (1996)			
	C56	*Mukoyama et al., J. Biol. Chem. 268(33):24539-24542 (1993)			
	C57	*Nials et al., Br. J. Pharmacol. 110:1112-1116 (1993)			
	C58	*Nials et al., Eur. J. Pharmacol. 251:127-135 (1994)			
	C59	*Nikko/Masato et al., Chem Abstract 113(2):354 #11917g (1990)			
	C60	*Nimchinsky et al., J. Biol. Chem. 272(46):29229-29237 (1997)			
	C61	*Ngo et al., Drugs Future 22(3):260-269 (1997)			
	C62	*Pauwels et al., Biochem. Pharmacol. 45(2):375-383 (1993)			
	C63	*Pauwels et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 353:144-156 (1996)			
	C64	*Piergentili et al. II Farmaco 49(2):83-87 (1994)			
	C65	*Portoghese, J. Med. Chem. 35(11):1927-1937 (1992)			
	C66	*Riyero et al., Bioorg. Med. Chem. Lett. 3(4):557-560 (1993)			
	C67	*Ruffolo et al., J. Med Chem. 38(19):3681-3716 (1995)			
EXAMINER		DATE CONSIDERED 6/3/05			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 Approved for use through 10/31/2002 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Attorney's Docket No. AMI-011-RC2	Serial No. 10/015,534
				Applicant Burton G. Christensen et al.	
				Filing Date December 13, 2001	Group Art Unit 1627
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
	C68	*Schoeffter et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 340:135-138 (1989)			
	C69	*Shuker et al., Science 274:1531-1534 (1996)			
	C70	*Suh et al., Bioorg. Med. Chem. Lett. 7(4):389-392 (1997)			
	C71	*Valentin et al., Br. J. Pharmacol. 119:35-42 (1996)			
	C72	*Van de Water et al., Eur. J. Pharmacol. 299:127-137 (1996)			
	C73	*Veldman et al., Mol. Pharmacol. 42:439-444 (1992)			
	C74	*Waldeck et al., Eur. J. Pharmacol. 112(3):349-353 (1985)			
previously	C75	*Waldeck et al., Acta Pharmacol. Toxicol. 58:209-218 (1986)			
considered	C76	*Wexler et al., J. Med. Chem. 39(3):625-656 (1996)			
	C77	*Wong et al., JPET 252(2):719-725 (1990)			
	C78	*Wong et al., JPET 252(2):726-732 (1990)			
	C79	*Wurch et al., Br. J. Pharmacol. 120:153-159 (1997)			
	C80	*Yocca, Cephalgia 15(Suppl 14):174- (1995)			
	C81	*Zakon, Trends Neurosci. 21:202-207 (1998)			
	C82	*Zeng et al., J. Chrom. A 794:3-13 (1998)			
	C83	*Zgombick et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 54:226-236 (1996)			
	C84				
	C85				
	C86				
	C87				
	C88				
	C89				
	C90				
	C91				
	C92				
	C93				
	C94				
	C95				
	C96				
	C97				
EXAMINER		DATE CONSIDERED 6/3/05			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					